SCHEMBL21572795

SCHEMBL21572795

COC[C@H](C)CC(=O)Cc1ccc(-c2ccccc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.49
▸ LMNA P02545 2/20 0.49
▸ TSHR P16473 2/20 0.49
▸ ABCC4 O15439 1/20 0.49
▸ PTGS1 P23219 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ ALDH1A1 P00352 3/20 0.47
▸ HPGD P15428 2/20 0.47
▸ MAPT P10636 1/20 0.47
▸ MMP12 P39900 2/20 0.46
▸ KMT2A Q03164 3/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ PPARG P37231 1/20 0.42
▸ PPARD Q03181 1/20 0.42
▸ PPARA Q07869 1/20 0.42
▸ FAAH O00519 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21572788 0.87 TSHR (0.47) GAALMNATSHRABCC4PTGS1
SCHEMBL21572794 0.86 GAA (0.46) GAALMNATSHRABCC4PTGS1
SCHEMBL21572803 0.85 GAA (0.45) GAALMNATSHRABCC4PTGS1
SCHEMBL21572801 0.85 LMNA (0.45) GAALMNATSHRABCC4PTGS1
SCHEMBL21572810 0.85 GAA (0.45) GAALMNATSHRABCC4PTGS1
SCHEMBL21572797 0.83 LMNA (0.53) GAALMNATSHRABCC4PTGS1
SCHEMBL20583639 0.82 GAA (0.43) GAALMNATSHRABCC4PTGS1
SCHEMBL20583244 0.82 GAA (0.43) GAALMNATSHRABCC4PTGS1
SCHEMBL20583638 0.82 GAA (0.43) GAALMNATSHRABCC4PTGS1
SCHEMBL20583245 0.82 GAA (0.43) GAALMNATSHRABCC4PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11370739-B2 Sacubitril intermediate and preparation method thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2022-06-28 — — US disclosed
EP-3424899-B1 SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2022-05-11 — — EP disclosed
US-10479753-B2 Sacubitril intermediate and preparation method thereof SUNSHINE LAKE PHARMA CO., LTD (CN) 2019-11-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11370739-B2 Sacubitril intermediate and preparation method thereof DPP4, ACE, DPP8 GAA 63/4885LMNA 1222/4885TSHR 3965/4885
US-10479753-B2 Sacubitril intermediate and preparation method thereof ACE, DPP4, SI GAA 63/4885LMNA 2313/4885TSHR 3906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback